Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

WS3 - Host Genetics

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.

stratification DNA magnifying glass

 

Work Strand 3 focuses on stratification through assessment of the host genome

Identifying the genetic variants that influence clinically relevant treatment phenotypes may give insight into disease biology, which can inform on potential biomarkers or therapeutic targets. Genetic variants may also be used to stratify individuals on the basis of their predisposition to disease progression (e.g. liver cancer in patients with cirrhosis), treatment response or drug-associated side effects.

The objective of this Work Strand is to use a combination of genome-wide SNP arrays, DNA and RNA sequencing and direct genotyping to investigate the potential for patient stratification based on host genetics.

This Work Strand is led by Dr Chris Spencer (University of Oxford).